Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
|Articles|May 11, 2010
Conditions Recommended for Addition
Should the Task Force add more conditions to DSM5? If so, what are they? Some of the recommendations for addition include:
Advertisement
Should the Task Force add more conditions to DSM5? If so, what are they? Some of the recommendations for addition include:
• Apathy Syndrome
• Body Integrity Identity Disorder
• Complicated Grief Disorder
• Developmental Trauma Disorder
• Disorders of Extreme Stress
• Fetal Alcohol Syndrome
• Internet Addiction
• Male-to-Eunuch Gender Identity Disorder
• Melancholia
• Parental Alienation Disorder
• Seasonal Affective Disorder
• Sensory Processing Disorder
Related Content
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
2
New Adult ADHD Guidelines: What Resources Are Coming Soon
3
Vol 43, Issue 9 - Interactive
4
What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice
5